August 2022 | Targeted Therapies in Oncology

ISGIO® Seeks to Clarify Gastrointestinal Cancer Updates for the Clinic

August 31, 2022

Clinical Articles

During the Annual Meeting of the International Society of Gastrointestinal Oncology, experts in the field and investigators from pivotal studies will elucidate how these advances can be used to guide treatment, and how to choose between available treatments in specific patient populations.

Guidelines Provide Strategies for Managing Common irAEs

August 29, 2022

Clinical Articles

To assist clinicians in identifying, monitoring, and managing immune-related adverse effects, the American Society of Clinical Oncology issued guidelines in June 2022 updated by a multidisciplinary panel.

Hormone Therapy Discontinuation Rates Differ From Those in Randomized Trials

August 29, 2022

Clinical Articles

Hot flashes related to adjuvant hormone therapy were predictive of worse breast cancer outcomes, according to research on disease-free survival and treatment discontinuation in patients with and without hot flashes.

Two Genes Predict Resistance to ICIs in dMMR/ MSI-H GI Cancers

August 29, 2022

Clinical Articles

Two genes to assist in determining primary resistance to immunotherapy for patients with mismatch repair–deficient/microsatellite instability–high gastrointestinal cancers have been identified.

Durvalumab Triplet Improves OS Across Biliary Tract Cancer Locations

August 23, 2022

Clinical Articles

In findings presented at the ESMO World Congress on Gastrointestinal Cancer 2022, patients with intrahepatic and extrahepatic cholangiocarcinoma who were treated with the durvalumab triplet regimen demonstrated improved overall survival compared with the chemotherapy doublet.

Pelabresib and Ruxolitinib Combination Proves Durable in Patients With Myelofibrosis

August 21, 2022

Clinical Articles

Results from the MANIFEST study of pelabresib and ruxolitinib in myelfibrosis are positive. The phase MANIFEST-2 study continue to explored the combination in JAK inhibitor–naïve patients with myelofibrosis.

Talquetamab/Daratumumab Combination Appears Safe in Patients With Anti-CD38–Refractory Myeloma

August 18, 2022

Clinical Articles

The combination of talquetamab and daratumumab has the potential to demonstrate synergistic clinical activity, and preclinical studies have shown that the addition of daratumumab enhanced talquetamabmediated lysis of multiple myeloma cells.

Interleukin-Based Treatments Find Footing in Ongoing Research

August 16, 2022

Clinical Articles

Current- generation cytokines are being engineered to extend their half-life and improve tumor targeting using polyethylene glycol conjugation, fusion to tumor-targeting antibodies, alterations of cytokine/cell receptor–binding affinity, and other strategies.

Can Just-in-Time Clinical Trials Reduce Disparities in Participation?

August 16, 2022

Clinical Articles

Just-in-time trials are 1 tool capable of rapidly increasing access to clinical trials to develop drugs that treat the diverse and unique tapestry of patients across the United States, especially patients with more diverse racial, ethnic, and socioeconomic backgrounds.